JP5894533B2 - リン−タンパク質比の計算方法 - Google Patents

リン−タンパク質比の計算方法 Download PDF

Info

Publication number
JP5894533B2
JP5894533B2 JP2012532359A JP2012532359A JP5894533B2 JP 5894533 B2 JP5894533 B2 JP 5894533B2 JP 2012532359 A JP2012532359 A JP 2012532359A JP 2012532359 A JP2012532359 A JP 2012532359A JP 5894533 B2 JP5894533 B2 JP 5894533B2
Authority
JP
Japan
Prior art keywords
patient
phosphorus
time interval
predetermined time
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012532359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013506845A5 (cg-RX-API-DMAC7.html
JP2013506845A (ja
Inventor
ゴッチ,フランク,エイ.
ステネット,アマンダ,ケイ.
オフストン,ノーマ,ジェイ.
Original Assignee
フレゼニウス メディカル ケア ホールディングス インコーポレイテッド
フレゼニウス メディカル ケア ホールディングス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フレゼニウス メディカル ケア ホールディングス インコーポレイテッド, フレゼニウス メディカル ケア ホールディングス インコーポレイテッド filed Critical フレゼニウス メディカル ケア ホールディングス インコーポレイテッド
Publication of JP2013506845A publication Critical patent/JP2013506845A/ja
Publication of JP2013506845A5 publication Critical patent/JP2013506845A5/ja
Application granted granted Critical
Publication of JP5894533B2 publication Critical patent/JP5894533B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/11—Automated chemical analysis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/15—Inorganic acid or base [e.g., hcl, sulfuric acid, etc. ]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/16—Phosphorus containing
    • Y10T436/166666—Phosphorus containing of inorganic phosphorus compound in body fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Primary Health Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2012532359A 2009-10-01 2010-10-01 リン−タンパク質比の計算方法 Expired - Fee Related JP5894533B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27793509P 2009-10-01 2009-10-01
US61/277,935 2009-10-01
PCT/US2010/051155 WO2011041697A1 (en) 2009-10-01 2010-10-01 Method of calculating a phosphorus-protein ratio

Publications (3)

Publication Number Publication Date
JP2013506845A JP2013506845A (ja) 2013-02-28
JP2013506845A5 JP2013506845A5 (cg-RX-API-DMAC7.html) 2013-10-17
JP5894533B2 true JP5894533B2 (ja) 2016-03-30

Family

ID=43037782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012532359A Expired - Fee Related JP5894533B2 (ja) 2009-10-01 2010-10-01 リン−タンパク質比の計算方法

Country Status (5)

Country Link
US (1) US8822225B2 (cg-RX-API-DMAC7.html)
EP (1) EP2483685B1 (cg-RX-API-DMAC7.html)
JP (1) JP5894533B2 (cg-RX-API-DMAC7.html)
AU (1) AU2010300386B2 (cg-RX-API-DMAC7.html)
WO (1) WO2011041697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8845570B2 (en) 2010-04-16 2014-09-30 Baxter International Inc. Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis
US9132219B2 (en) 2010-04-16 2015-09-15 Baxter International Inc. Therapy prediction and optimization of serum potassium for renal failure blood therapy, especially home hemodialysis
US12040090B2 (en) 2019-04-04 2024-07-16 Kpn Innovations, Llc. Systems and methods for generating alimentary instruction sets based on vibrant constitutional guidance
US12159716B2 (en) 2019-04-04 2024-12-03 Kpn Innovations, Llc. Methods and systems for generating an alimentary instruction set identifying an individual prognostic mitigation plan
US10553316B1 (en) 2019-04-04 2020-02-04 Kpn Innovations, Llc Systems and methods for generating alimentary instruction sets based on vibrant constitutional guidance
US11222727B2 (en) 2019-04-04 2022-01-11 Kpn Innovations, Llc Systems and methods for generating alimentary instruction sets based on vibrant constitutional guidance
US12646619B2 (en) 2019-04-04 2026-06-02 Kpn Innovations, Llc Systems and methods for generating alimentary instruction sets based on vibrant constitutional guidance
US11315684B2 (en) 2019-04-04 2022-04-26 Kpn Innovations, Llc. Systems and methods for generating alimentary instruction sets based on vibrant constitutional guidance
US11322255B2 (en) 2019-04-04 2022-05-03 Kpn Innovations, Llc. Methods and systems for self-fulfillment of an alimentary instruction set based on vibrant constitutional guidance
US11594316B2 (en) 2020-05-04 2023-02-28 Kpn Innovations, Llc. Methods and systems for nutritional recommendation using artificial intelligence analysis of immune impacts
US11875889B2 (en) 2020-05-29 2024-01-16 Kpn Innovations, Llc. Methods and systems of alimentary provisioning
US12009085B2 (en) 2020-07-27 2024-06-11 Kpn Innovations, Llc. Systems and methods for scheduling alimentary combinations
US11393572B2 (en) 2020-11-03 2022-07-19 Kpn Innovations, Llc. System and method for modifying a nutrition requirement

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884124B2 (ja) * 1992-01-31 1999-04-19 鈴与株式会社 リン吸着剤
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
US20040193446A1 (en) 2003-03-27 2004-09-30 Mayer Steven Lloyd System and method for managing a patient treatment program including a prescribed drug regimen
JP4633552B2 (ja) * 2005-06-22 2011-02-16 株式会社テクノメディカ 腎臓機能コントロール状態測定方法及び測定システム
CN105468895A (zh) * 2006-05-02 2016-04-06 普罗透斯数字保健公司 患者定制的治疗方案

Also Published As

Publication number Publication date
WO2011041697A1 (en) 2011-04-07
AU2010300386B2 (en) 2014-03-20
AU2010300386A1 (en) 2012-04-12
EP2483685A1 (en) 2012-08-08
US8822225B2 (en) 2014-09-02
JP2013506845A (ja) 2013-02-28
US20120184036A1 (en) 2012-07-19
EP2483685B1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
US8822225B2 (en) Method of calculating a phosphorus-protein ratio
Abosaif et al. The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability
Menon et al. Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study
Cianciaruso et al. Effect of a low-versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial
Doizi et al. Impact of potassium citrate vs citric acid on urinary stone risk in calcium phosphate stone formers
Kestenbaum et al. Parathyroidectomy rates among United States dialysis patients: 1990–1999
Sayers et al. An observational study using blood gas analysis to assess neonatal calf diarrhea and subsequent recovery with a European Commission-compliant oral electrolyte solution
Kloppenburg et al. Assessing dialysis adequacy and dietary intake in the individual hemodialysis patient
JP2015091411A (ja) 透析患者のためのリン酸塩結合剤投与量の決定方法
Zeng et al. International Alliance of Urolithiasis (IAU) guidelines on the metabolic evaluation and medical management of urolithiasis
Kubiak et al. Mineral metabolism disturbances and arteriovenous fistula maturation
Tiselius Medical evaluation of nephrolithiasis
Ino et al. Multidisciplinary team care delays the initiation of renal replacement therapy in diabetes: a five-year prospective, single-center study
Samarron et al. Homocysteine is associated with severity of microvasculopathy in sickle cell disease patients
den Bakker et al. Assessment of kidney function in children
Jean et al. Usefulness and feasibility of measuring ionized calcium in haemodialysis patients
Muntner et al. Metabolic abnormalities are present in adults with elevated serum cystatin C
Stegeman et al. Determination of protein catabolic rate in patients on chronic intermittent hemodialysis: Urea output measurements compared with dietary protein intake and with calculation of urea generation rate
Hegbrant et al. Residual renal phosphate clearance in patients receiving hemodialysis or hemodiafiltration
Chun-yan et al. Low-dose dialysis combined with low protein intake can maintain nitrogen balance in peritoneal dialysis patients in poor economies
Chun-yan et al. Peritoneal dialysis can maintain nitrogen balance with low Kt/V in anuric patients
Coulter et al. The pharmacokinetics of methanol in the presence of ethanol: a case study
Rendina et al. Characteristic clinical and biochemical profile of recurrent calcium-oxalate nephrolithiasis in patients with metabolic syndrome
Mercadal et al. MON-111 Effect of the dialysate calcium concentration and of the mineral bone disease therapies on mortality in the REIN registry
Jusufovic et al. Role of renal anemia in the functional, morphological and autoimmune thyroid disorders in patients on chronic hemodialysis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130902

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160226

R150 Certificate of patent or registration of utility model

Ref document number: 5894533

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees